Welcome to the State of California 

MDL logo

Test Order

Mycobacterium tuberculosis Complex:
Drug Susceptibility Testing, Second Line

Pre-Approval Required

None

Supplemental Information or Form

Form LAB 444 (03/12) (MDL-N-25), EXAMINATION FOR MYCOBACTERIUM TUBERCULOSIS DRUG SUSCEPTIBILITY  

Performed on Specimens from

California local public health laboratories

Acceptable Sample/Specimen Type for Testing

Pure culture

Minimum Volume Required

None

Storage & Preservation of Specimen Prior to Shipping

Incubated at 35-37°C (or refrigerated)

Transport Medium

None

Specimen Labeling

Patient’s name, accession number, inoculation or subculture date 

Shipping Instructions which Include Specimen Handling Requirements

Ship as infectious substance.

Test Methodology

MGIT 960. Drugs tested are amikacin 1.5 µg/ml, moxifloxacin 0.25 µg/ml, capreomycin 3µg/ml, and ethionamide 5µg/ml.  If susceptible to moxifloxacin at 0.25 μg/ml, this predicts susceptibility to levofloxacin as well.  When resistant to moxifloxacin at 0.25 µg/ml, testing moxifloxacin MIC at 0.5, 1, 2, and 3 μg/ml is performed.  If the initial testing shows ethionamide resistance, testing at 5 µg/ml and 10 µg/ml is performed.

Turnaround Time

around 2 weeks

Interferences & Limitations

Results unattainable because culture submitted is not pure.

Additional Information

None

MDL Points of Contact

Mycobacterial Diseases Section (drug susceptibilities) (510) 412-3929 Email: grace.lin@cdph.ca.gov

 
 
Last modified on: 8/26/2016 11:14 AM